干扰素联合保妇康栓治疗宫颈高危型HPV感染疗效及对阴道微生态环境的影响分析
|
摘要
目的分析宫颈高危型HPV感染患者行干扰素联合保妇康栓治疗的价值,同时记录对阴道微生态环境的影响。方法纳入该院于2015年12月—2017年1月收治的宫颈HPV感染患者60例,根据治疗方法的不同将其平均分为观察组和对照组,每组30例。观察组行保妇康栓联合干扰素治疗,对照组行单一干扰素救治,对比两组治疗后的HPV转阴情况、治疗后90 d阴道微生态恢复情况、治疗前后宫颈局部微生态环境中的免疫炎症因子水平。结果①观察组患者转阴率76.7%优于对照组50.0%、两组对比统计学意义形成(χ~2=4.355 6、P<0.05);②治疗后90 d阴道微生态恢复情况分析,观察组恢复率83.3%高于对照组60.0%(χ~2=4.021 9 P<0.05),阴道分泌物pH值对比,观察组(4.1±0.6)优于对照组(4.5±0.7),差异有统计学意义(t=2.376 3,P=0.020 8),Nugent分数分析,观察组(2.2±0.4)优于对照组(3.0±0.7),组间对比差异有统计学意义(t=5.434 9,P=0.000 0);③治疗前后宫颈局部微生态环境中的免疫炎症因子水平分析,治疗后90 d两组的IL-4水平有所降低,其IL-12和IFN-有所提高,治疗后观察组改善程度优于对照组,组间对比差异有统计学意义(t=4.4337、3.1609、2.4046 P<0.05)。结论将保妇康栓联合干扰素应用于宫颈HPV病毒感染患者中,其转阴率显著提升,临床指标有效改善。
Objective To analyze the value of interferon combined with Baofukang suppository in patients with high-risk HPV infection,and to record the impact on vaginal micro-ecological environment. Methods 60 patients with cervical HPV infection admitted to our hospital from December 2015 to January 2017 were divided into observation group and control group according to different treatment methods, 30 cases in each group. The observation group was treated with Baofukang suppository combined with interferon. The control group received a single interferon treatment. The HPV negative condition after treatment, the vaginal microecological recovery after 90 days of treatment, and the local micro-ecological environment of the cervix immune inflammatory factor levels before and after treat-ment were compared. Results 1.The observation group had a negative rate of 76.7%, which was better than 50% of the control group.The statistical significance of the two groups was formed,the difference wasstatistically significant(χ~2=4.355 6, P<0.05); 2.90 days after treatment vaginal micro-ecological recovery analysis showed that the recovery rate of the observation group was 83.3% higher than that of the control group 60.0%,the difference wasstatistically significant(χ~2=4.021 9, P<0.05), and the pH value of vaginal secretions was better than that of the control group(4.5±0.7),the difference wasstatistically significant(t=2.376 3, P=0.020 8), Nugent score analysis, observation group(2.2±0.4) was better than control group(3.0±0.7), the comparison between groups was statistically significant(t=5.434 9, P=0.000 0); 3.before treatment, the levels of immunoinflammatory factors in the local micro-ecological environment of the cervix were reduced. The IL-4 levels of the two groups were decreased on the 90 th day after treatment, and the IL-12 and IFN-levels were improved. The improvement of the observation group after treatment was better than that of the control group. The comparison between groups was statistically significant(t=4.4337, 3.1609, 2.4046, P<0.05). Conclusion The combination of Baofukang suppository and interferon in patients with cervical HPV infection has significantly improved the negative conversion rate and improved the clinical indicators.
Objective To analyze the value of interferon combined with Baofukang suppository in patients with high-risk HPV infection,and to record the impact on vaginal micro-ecological environment. Methods 60 patients with cervical HPV infection admitted to our hospital from December 2015 to January 2017 were divided into observation group and control group according to different treatment methods, 30 cases in each group. The observation group was treated with Baofukang suppository combined with interferon. The control group received a single interferon treatment. The HPV negative condition after treatment, the vaginal microecological recovery after 90 days of treatment, and the local micro-ecological environment of the cervix immune inflammatory factor levels before and after treat-ment were compared. Results 1.The observation group had a negative rate of 76.7%, which was better than 50% of the control group.The statistical significance of the two groups was formed,the difference wasstatistically significant(χ~2=4.355 6, P<0.05); 2.90 days after treatment vaginal micro-ecological recovery analysis showed that the recovery rate of the observation group was 83.3% higher than that of the control group 60.0%,the difference wasstatistically significant(χ~2=4.021 9, P<0.05), and the pH value of vaginal secretions was better than that of the control group(4.5±0.7),the difference wasstatistically significant(t=2.376 3, P=0.020 8), Nugent score analysis, observation group(2.2±0.4) was better than control group(3.0±0.7), the comparison between groups was statistically significant(t=5.434 9, P=0.000 0); 3.before treatment, the levels of immunoinflammatory factors in the local micro-ecological environment of the cervix were reduced. The IL-4 levels of the two groups were decreased on the 90 th day after treatment, and the IL-12 and IFN-levels were improved. The improvement of the observation group after treatment was better than that of the control group. The comparison between groups was statistically significant(t=4.4337, 3.1609, 2.4046, P<0.05). Conclusion The combination of Baofukang suppository and interferon in patients with cervical HPV infection has significantly improved the negative conversion rate and improved the clinical indicators.
引文
[1]李婵玉.重组人干扰素α2b联合保妇康栓在宫颈高危型HPV感染治疗中的应用[J].中外女性健康研究,2018(24):39,41.
[2]唐梅艳,唐冬艳,陈欢.保妇康联合干扰素治疗宫颈高危型HPV感染的临床研究[J].当代医学,2018,24(6):91-93.
[3]朱坤侠.重组人干扰素α-2a栓联合保妇康栓治疗宫颈高危型HPV感染的效果观察[J].河南医学研究,2018,27(4):723-724.
[4]许彩芹,李艳华,李颖敏,等.保妇康栓和干扰素联合中药治疗低度宫颈上皮内瘤变合并高危型HPV感染的疗效观察[J].中国妇幼保健,2017,32(20):4932-4934.
[5]张晓纯.保妇康栓联合干扰素治疗高危型HPV感染临床观察[J].中医临床研究,2017,9(27):87-90.
[6]柴洪佳.保妇康栓治疗宫颈高危型人乳头状病毒持续感染患者的疗效观察[J].黑龙江医药,2018,31(2):314-316.
[7]胡静熠.保妇康栓联合重组人干扰素栓治疗高危型人乳头状病毒持续感染效果观察[J].江苏预防医学,2017,28(6):704-705.
[8]刘红梅,黄雪玉,刘小艳,等.重组人干扰素α2b凝胶联合保妇康栓治疗宫颈高危型HPV感染的疗效观察[J].广东医学院学报,2016,34(3):312-313.
[9]周小燕,罗一平,梁洁意.重组人干扰素α-2b栓联合乳酸菌阴道胶囊治疗宫颈高危型HPV感染的效果及对微生态环境相关免疫因子的影响[J].山西医药杂志, 2017(4).
[10]许彩芹,李艳华,李颖敏,等.保妇康栓和干扰素联合中药治疗低度宫颈上皮内瘤变合并高危型HPV感染的疗效观察[J].中国妇幼保健,2017(20):4932-4934.
[11]徐颜红.保妇康栓和干扰素α2b栓治疗高危型宫颈HPV持续性感染的效果比较[J].河南医学研究,2016,25(9):1634-1635.
[12]杨红娟,戴淑真,王而, IL-4和IL-12在宫颈癌的表达及临床意义[J].现代妇产科进展, 2011, 20(2):128-130.
[2]唐梅艳,唐冬艳,陈欢.保妇康联合干扰素治疗宫颈高危型HPV感染的临床研究[J].当代医学,2018,24(6):91-93.
[3]朱坤侠.重组人干扰素α-2a栓联合保妇康栓治疗宫颈高危型HPV感染的效果观察[J].河南医学研究,2018,27(4):723-724.
[4]许彩芹,李艳华,李颖敏,等.保妇康栓和干扰素联合中药治疗低度宫颈上皮内瘤变合并高危型HPV感染的疗效观察[J].中国妇幼保健,2017,32(20):4932-4934.
[5]张晓纯.保妇康栓联合干扰素治疗高危型HPV感染临床观察[J].中医临床研究,2017,9(27):87-90.
[6]柴洪佳.保妇康栓治疗宫颈高危型人乳头状病毒持续感染患者的疗效观察[J].黑龙江医药,2018,31(2):314-316.
[7]胡静熠.保妇康栓联合重组人干扰素栓治疗高危型人乳头状病毒持续感染效果观察[J].江苏预防医学,2017,28(6):704-705.
[8]刘红梅,黄雪玉,刘小艳,等.重组人干扰素α2b凝胶联合保妇康栓治疗宫颈高危型HPV感染的疗效观察[J].广东医学院学报,2016,34(3):312-313.
[9]周小燕,罗一平,梁洁意.重组人干扰素α-2b栓联合乳酸菌阴道胶囊治疗宫颈高危型HPV感染的效果及对微生态环境相关免疫因子的影响[J].山西医药杂志, 2017(4).
[10]许彩芹,李艳华,李颖敏,等.保妇康栓和干扰素联合中药治疗低度宫颈上皮内瘤变合并高危型HPV感染的疗效观察[J].中国妇幼保健,2017(20):4932-4934.
[11]徐颜红.保妇康栓和干扰素α2b栓治疗高危型宫颈HPV持续性感染的效果比较[J].河南医学研究,2016,25(9):1634-1635.
[12]杨红娟,戴淑真,王而, IL-4和IL-12在宫颈癌的表达及临床意义[J].现代妇产科进展, 2011, 20(2):128-130.